| Autor: |
Ogbuagu, Onyema, Segal-Maurer, Sorana, Ratanasuwan, Winai, Avihingsanon, Anchalee, Brinson, Cynthia, Workowski, Kimberly, Antinori, Andrea, Yazdanpanah, Yazdan, Trottier, Benoit, Wang, Hui, Margot, Nicolas, Dvory-Sobol, Hadas, Rhee, Martin S, Baeten, Jared M, Molina, Jean-Michel, DeJesus, Edwin, Richmond, Gary J., Berhe, Mezgebe, Ruane, Peter J., Sinclair, Gary Ian, Lichtenstein, Kenneth, Ramgopal, Moti N., Wiznia, Andrew, Workowski, Kimberly, Sanchez, William, Brinson, Cynthia, McGowan, Joseph P., Creticos, Catherine M., Berger, Daniel S., Wheeler, David A., Hagins, Debbie, Crofoot, Gordon E., Sims, James, Osiyemi, Olayemi, Hodge, Theo, Zurawski, Christine, Ogbuagu, Onyema, Segal-Maurer, Sorana, Ratanasuwan, Winai, Avihingsanon, Anchalee, Siripassorn, Krittaecho, Chetchotisakd, Ploenchan, Castagna, Antonella, Antinori, Andrea, Castelli, Francesco, Ronot-Bregigeon, Sylvie, Molina, Jean-Michel, Yazdanpanah, Yazdan, Trottier, Benoit, Brunetta, Jason, Shirasaka, Takuma, Yokomaku, Yoshiyuki, Koenig, Ellen, Mallolas, Josep, Stellbrink, Hans-Jurgen, Hung, Chien-Ching, Rassool, Mohammed |
| Zdroj: |
The Lancet HIV; August 2023, Vol. 10 Issue: 8 pe497-e505, 9p |
| Abstrakt: |
Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 weeks. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
